This $700,611 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) aims to conduct a practical randomized controlled trial (RCT) to determine the impact of using artificial intelligence (AI) as a second opinion to enhance the competence of dermatologists in classifying dermoscopy photos for melanoma diagnosis. The trial will be executed at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU), with a focus on addressing potential AI biases through diverse recruitment, performance monitoring, and expert oversight. The project will lay the groundwork for future multi-center clinical trials to evaluate this AI technology for widespread clinical adoption in melanoma detection. The award has an initial period of performance from March 2025 to February 2030.
Generated 3/25/25, 6:00 AM